

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210875Orig1s000

LABELING

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use KYNMOBI safely and effectively. See full prescribing information for KYNMOBI.

KYNMOBI™ (apomorphine hydrochloride) sublingual film

Initial U.S. Approval: 2004

INDICATIONS AND USAGE

KYNMOBI is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease (1)

DOSAGE AND ADMINISTRATION

- For sublingual administration only (2.1)
- Dose initiation should be supervised by a healthcare provider (2.1, 2.3)
- Treatment with a concomitant antiemetic, e.g. trimethobenzamide, is recommended, beginning 3 days prior to initial dose of KYNMOBI (2.1, 5.1)
- The dose range for KYNMOBI is 10 mg to 30 mg per dose, administered sublingually, as needed (2.2)
- KYNMOBI doses should be separated by at least 2 hours (2.2)
- Maximum of 5 doses per day; maximum single dose is 30 mg (2.2, 2.3)

DOSAGE FORMS AND STRENGTHS

KYNMOBI sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg of apomorphine hydrochloride (3, 16)

CONTRAINDICATIONS

- Concomitant use of KYNMOBI with 5HT3 antagonists (4)
- Hypersensitivity to apomorphine or any of its ingredients including sodium metabisulfite (4)

WARNINGS AND PRECAUTIONS

- Nausea and vomiting may occur (2.1, 5.1)
- Falling asleep during activities of daily living and daytime somnolence may occur, discontinue KYNMOBI if occurs (5.2)

- Syncope and hypotension/orthostatic hypotension may occur, monitor blood pressure (5.3)
- Oral mucosal irritation may occur, which may require pausing or discontinuing treatment (5.4)
- Falls may occur, or increase (5.6)
- May cause hallucinations and psychotic-like behavior (5.7)
- May cause impulse control and impulsive behaviors; consider dose reduction or discontinuing KYNMOBI if occurs (5.8)
- Withdrawal-emergent hyperpyrexia and confusion may occur with rapid dose reduction or withdrawal (5.9)
- May prolong QTc and cause torsades de pointes or sudden death; consider risk factors prior to initiation (5.10)

ADVERSE REACTIONS

Most common adverse reactions (incidence at least 10% in patients treated with KYNMOBI and with an incidence greater than placebo) were nausea, oral/pharyngeal soft tissue swelling, oral/pharyngeal soft tissue pain and paraesthesia, dizziness, and somnolence (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 1-877-737-7226 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Concomitant use of antihypertensive medications and vasodilators may increase risk for hypotension, myocardial infarction, falls and injuries (7.2)
- Dopamine antagonists may diminish the effectiveness of KYNMOBI (7.4)

USE IN SPECIFIC POPULATIONS

- Pregnancy: Based on animal data, may cause fetal harm (8.1)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 5/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1	INDICATIONS AND USAGE	7.4	Dopamine Antagonists
2	DOSAGE AND ADMINISTRATION	7.5	Drugs Prolonging the QT/QTc Interval
2.1	Important Administration Instructions	8	USE IN SPECIFIC POPULATIONS
2.2	Dosing Information	8.1	Pregnancy
2.3	Dose Titration	8.2	Lactation
3	DOSAGE FORMS AND STRENGTHS	8.4	Pediatric Use
4	CONTRAINDICATIONS	8.5	Geriatric Use
5	WARNINGS AND PRECAUTIONS	8.6	Renal Impairment
5.1	Nausea and Vomiting	8.7	Hepatic Impairment
5.2	Falling Asleep During Activities of Daily Living and Somnolence	9	DRUG ABUSE AND DEPENDENCE
5.3	Hypersensitivity	9.1	Controlled Substance
5.4	Syncope / Hypotension / Orthostatic Hypotension	9.2	Abuse
5.5	Oral Mucosal Irritation	11	DESCRIPTION
5.6	Falls	12	CLINICAL PHARMACOLOGY
5.7	Hallucinations / Psychotic-Like Behavior	12.1	Mechanism of Action
5.8	Impulse Control/Compulsive Behaviors	12.2	Pharmacodynamics
5.9	Withdrawal-Emergent Hyperpyrexia and Confusion	12.3	Pharmacokinetics
5.10	QTc Prolongation and Potential for Proarrhythmic Effects	13	NONCLINICAL TOXICOLOGY
5.11	Fibrotic Complications	13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
5.12	Priapism	14	CLINICAL STUDIES
5.13	Retinal Pathology in Albino Rats	16	HOW SUPPLIED/STORAGE AND HANDLING
6	ADVERSE REACTIONS	16.1	How Supplied
6.1	Clinical Trials Experience	16.2	Storage and Handling
7	DRUG INTERACTIONS	17	PATIENT COUNSELING INFORMATION
7.1	5HT3 Antagonists		
7.2	Antihypertensive Medications and Vasodilators		
7.3	Alcohol		

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

KYNMOBI is indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease (PD).

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Instructions

Dose initiation should be supervised by a healthcare provider [*see Dosage and Administration (2.3)*].

KYNMOBI must be administered whole. Do not to cut, chew, or swallow KYNMOBI. KYNMOBI will disintegrate in about 3 minutes.

Because of the high incidence of nausea and vomiting with KYNMOBI when administered at recommended doses, an antiemetic (e.g., trimethobenzamide 300 mg three times a day), beginning 3 days prior to the initial dose of KYNMOBI, is recommended. Treatment with the antiemetic should only be continued as long as necessary to control nausea and vomiting, and generally no longer than two months after initiation of treatment with KYNMOBI [*see Contraindications (4) and Warnings and Precautions (5.1)*].

Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT₃ antagonist class including antiemetics (for example, ondansetron, granisetron, dolasetron, palonosetron) and alosetron are contraindicated [*see Contraindications (4)*].

2.2 Dosing Information

The dose range for KYNMOBI is 10 mg to 30 mg per dose, administered sublingually, as needed, for the acute, intermittent treatment of “off” episodes.

Doses should be separated by at least 2 hours. If a single dose of KYNMOBI is ineffective for a particular “off” episode, a second dose should not be given for that “off” episode. The efficacy or safety of administering a second dose for a single “off” episode has not been studied.

Do not administer more than 5 doses per day.

The maximum single dose of KYNMOBI is 30 mg.

2.3 Dose Titration

The initial dose is 10 mg. Dose initiation should occur when the patient is in an “off” state and in a setting where a healthcare provider can monitor blood pressure and pulse. In clinical studies of KYNMOBI, the “off” state was achieved by instructing patients to not take their regular morning dose of carbidopa/levodopa or any other adjunctive Parkinson’s disease medications, and to take their last dose of carbidopa/levodopa and any other adjunctive Parkinson’s disease medications no later than midnight the night before [*see Clinical Studies (14)*].

If the patient tolerates the 10 mg dose, and responds adequately, the starting dose should be 10 mg, used on an as needed basis, up to 5 times per day, to treat “off” episodes. If the dose is tolerated but the response is insufficient, the patient’s usual Parkinson’s disease medications should be resumed and up-titration with KYNMOBI continued generally within 3 days. Increase dosage by increments of 5 mg and assess response. Continue to titrate in a similar manner, under the supervision of a healthcare provider, until an effective and tolerable dose is achieved [*see Dosage and Administration (2.2) and Clinical Studies (14)*].

3 DOSAGE FORMS AND STRENGTHS

KYNMOBI sublingual film is a blue to green rectangular film with a white printed number identifying the strength (e.g., “10” is 10 mg). KYNMOBI comes in dosage strengths of 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg. Each sublingual film is individually packaged in a sealed foil pouch.

4 CONTRAINDICATIONS

KYNMOBI is contraindicated in patients:

- Using concomitant 5HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [*see Drug Interactions (7.1)*]. There have been reports of profound hypotension and loss of consciousness when subcutaneous apomorphine was administered with a 5HT3 antagonist.
- With hypersensitivity/allergic reaction to apomorphine or to any of the ingredients of KYNMOBI. Angioedema or anaphylaxis may occur [*see Warnings and Precautions (5.3)*].

5 WARNINGS AND PRECAUTIONS

5.1 Nausea and Vomiting

KYNMOBI may cause nausea and vomiting when administered at recommended doses. Because of the high incidence of nausea and vomiting with KYNMOBI when administered at recommended doses, an antiemetic, e.g., trimethobenzamide 300 mg three times a day, is recommended beginning 3 days prior to the initial dose of KYNMOBI. Treatment with the antiemetic should only be continued as long as necessary to control nausea and vomiting, and generally no longer than two months after initiation of treatment with KYNMOBI [*see Dosage and Administration (2.1)*].

In Study 1 [*see Clinical Studies (14)*], treatment with an antiemetic (i.e., trimethobenzamide hydrochloride; 300 mg by mouth three times daily) was required beginning 3 days before starting KYNMOBI; however, it could be discontinued during the maintenance phase. During the titration phase of Study 1, nausea was reported as an adverse reaction by 21% of patients treated with KYNMOBI, while vomiting was reported as an adverse reaction by 4% of patients treated with KYNMOBI. During the maintenance phase of Study 1, nausea was reported as an adverse reaction by 28% of patients treated with KYNMOBI, compared with 4 % of patients who

received placebo. During the maintenance phase of Study 1, vomiting was reported as an adverse reaction by 7% of patients treated with KYNMOBI, compared with 0 % of patients who received placebo. Nausea or vomiting was the reason for withdrawal from the study in 2% of patients treated with KYNMOBI during the titration phase and 2% of patients treated with KYNMOBI during the maintenance phase.

Concomitantly administered antiemetic drugs other than trimethobenzamide have not been studied. 5HT₃ antagonist antiemetics are contraindicated [*see Contraindications (4)*].

Antiemetics with anti-dopaminergic actions (e.g., haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide) have the potential to worsen symptoms in patients with Parkinson's disease and should be avoided [*see Drug Interactions (7.4)*].

5.2 Falling Asleep During Activities of Daily Living and Somnolence

Patients treated with dopaminergic medications, including apomorphine, have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes has resulted in accidents. Patients may not perceive warning signs, such as excessive drowsiness, or they may report feeling alert immediately prior to the event.

During the titration phase of Study 1, somnolence was reported as an adverse reaction in 11% of patients treated with KYNMOBI. During the maintenance phase of Study 1, somnolence was reported as an adverse reaction in 13% of patients treated with KYNMOBI, compared with 2% of patients who received placebo.

Prescribers should reassess patients for drowsiness or sleepiness, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or sleepiness during specific activities.

Before initiating treatment with KYNMOBI, advise patients of the risk of drowsiness and ask them about factors that could increase the risk with KYNMOBI, such as concomitant sedating medications and the presence of sleep disorders. If a patient develops significant daytime sleepiness or falls asleep during activities that require active participation (e.g., conversations, eating, etc.), KYNMOBI should ordinarily be discontinued. If a decision is made to continue KYNMOBI, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to determine whether dose reduction will eliminate episodes of falling asleep while engaged in activities of daily living.

5.3 Hypersensitivity

Oral soft tissue swelling (lips, tongue, gingiva, and mouth) was reported as adverse reaction in 15% of patients treated with KYNMOBI during the maintenance phase of Study 1, compared with 0% of patients who received placebo; 11% of patients discontinued KYNMOBI because of this event.

Swelling of the face, oral allergy syndrome, hypersensitivity, or urticaria were reported as an adverse reaction in 6% of patients treated with KYNMOBI during the maintenance phase of Study 1, compared with 0% of patients who received placebo; 4% of patients discontinued KYNMOBI because of this event.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.